ELI LILLY AND COMPANY Gain (Loss) on Extinguishment of Debt
ELI LILLY AND COMPANY (LLY) reported Gain (Loss) on Extinguishment of Debt of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-21.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2024-02-21
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for the quarter ending 2022-12-31 was $0.00.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for the quarter ending 2022-09-30 was $0.00.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for the quarter ending 2021-12-31 was $0.00.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for the quarter ending 2021-09-30 was -$405.20M.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for fiscal 2023 was $0.00.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for fiscal 2022 was $0.00.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for fiscal 2021 was -$405.20M.
- ELI LILLY AND COMPANY gain (loss) on extinguishment of debt for fiscal 2020 was $0.00.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-21 | ||||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 10-K · filed 2024-02-21 | ||
| 2022-09-30 | $0.00 10-Q · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | -$405.20M derived: sum of 2 quarters · filed 2024-02-21 | -$405.20M 10-K · filed 2024-02-21 | ||
| 2021-09-30 | -$405.20M 10-Q · filed 2022-11-01 | -$405.20M 10-Q · filed 2022-11-01 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $0.00 derived: sum of 2 quarters · filed 2023-02-22 | $0.00 10-K · filed 2023-02-22 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-10-27 | $0.00 10-Q · filed 2021-10-27 | |||
| 2019-12-31 | -$252.50M 10-K · filed 2022-02-23 | ||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-17 | $242.10M 10-K · filed 2019-02-19 | |||
| 2017-12-31 | $0.00 10-K · filed 2020-02-19 | ||||
| 2016-12-31 | $197.10M derived: 8-K 12 month − 10-Q 9 month · filed 2019-10-24 | $197.10M derived: sum of 2 quarters · filed 2019-10-24 | $197.10M derived: sum of 3 quarters · filed 2019-10-24 | $197.10M 8-K · filed 2019-10-24 | $0.00 10-K · filed 2017-02-21 |
| 2016-09-30 | $0.00 10-Q · filed 2016-10-28 | $0.00 derived: sum of 2 quarters · filed 2016-10-28 | $0.00 10-Q · filed 2016-10-28 | $0.00 derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-06-30 | $0.00 10-Q · filed 2016-07-28 | $0.00 10-Q · filed 2016-07-28 | $0.00 derived: sum of 3 quarters · filed 2018-02-20 | $0.00 derived: sum of 4 quarters · filed 2018-02-20 | |
| 2016-03-31 | $0.00 10-Q · filed 2016-04-29 | $0.00 derived: sum of 2 quarters · filed 2018-02-20 | $0.00 derived: sum of 3 quarters · filed 2018-02-20 | -$166.70M derived: sum of 4 quarters · filed 2018-02-20 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-20 | $0.00 derived: sum of 2 quarters · filed 2018-02-20 | -$166.70M derived: sum of 3 quarters · filed 2018-02-20 | -$166.70M 10-K · filed 2018-02-20 | |
| 2015-09-30 | $0.00 10-Q · filed 2016-10-28 | -$166.70M derived: sum of 2 quarters · filed 2016-10-28 | -$166.70M 10-Q · filed 2016-10-28 | -$166.70M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-06-30 | -$166.70M 10-Q · filed 2016-10-28 | -$166.70M 10-Q · filed 2016-07-28 | -$166.70M derived: sum of 3 quarters · filed 2017-02-21 | -$166.70M derived: sum of 4 quarters · filed 2017-02-21 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-04-29 | $0.00 derived: sum of 2 quarters · filed 2017-02-21 | $0.00 derived: sum of 3 quarters · filed 2017-02-21 | $0.00 derived: sum of 4 quarters · filed 2017-02-21 | |
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-21 | $0.00 derived: sum of 2 quarters · filed 2017-02-21 | $0.00 derived: sum of 3 quarters · filed 2017-02-21 | $0.00 10-K · filed 2017-02-21 | |
| 2014-09-30 | $0.00 10-Q · filed 2015-10-30 | $0.00 derived: sum of 2 quarters · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | ||
| 2014-06-30 | $0.00 10-Q · filed 2015-07-30 | $0.00 10-Q · filed 2015-07-30 | |||
| 2013-12-31 | $0.00 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |